Related Experiment Video

Updated: Dec 26, 2025

Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells
10:03

Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells

Published on: July 5, 2019

9.3K

Targeting STAT-3 signaling pathway in cancer for development of novel drugs: Advancements and challenges

Sundas Arshad1, Muhammad Naveed2, Mahad Ullia3

  • 1University of Lahore, Department of Allied Health Sciences, Gujrat Campus, Pakistan.

Genetics and Molecular Biology
|March 14, 2020
PubMed

Insights

Signal transducer and activator of transcription 3 (STAT-3) is crucial in cancer development. Inhibiting STAT-3 signaling offers a promising therapeutic strategy for various cancers, with ongoing research into its effectiveness and limitations.

Area of Science:

  • Molecular biology
  • Oncology
  • Biochemistry

Background:

  • Signal transducer and activator of transcription 3 (STAT-3) is a transcription factor regulating gene expression.
  • STAT-3 activation is implicated in cellular processes including inflammation, survival, invasion, metastasis, proliferation, and angiogenesis.
  • Aberrant STAT-3 signaling is frequently observed in tumor development and cellular transformation.

Purpose of the Study:

  • To review the role of STAT-3 as a cancer drug target.
  • To discuss STAT-3 inhibitors and their antitumor effects.
  • To critically evaluate current limitations, trials, and future perspectives of STAT-3 inhibitors.

Main Methods:

  • Extensive literature review.
  • Analysis of genomic and pharmacological targeting methodologies for STAT-3.
  • Discussion of in vitro and in vivo studies on STAT-3 inhibitors.

Main Results:

  • STAT-3 pathway is activated by various stimuli including cytokines, growth factors, carcinogens, viruses, and oncogenes.
  • STAT-3 inhibitors demonstrate significant antitumor effects.
  • Targeting constitutive STAT-3 signaling is a viable therapeutic approach for tumor progression.

Conclusions:

  • STAT-3 is a validated and unique target for cancer therapeutics.
  • STAT-3 inhibitors represent a promising class of anticancer agents.
  • Further research is needed to overcome limitations and optimize clinical applications of STAT-3 inhibitors.

More Related Videos

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening05:54

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

9.0K
A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K